Iqvia Holdings Inc (NYSE: IQV) has reported E.P.S. of $1.58 for its first fiscal quarter (ending March 31) versus $1.56 for the same period a year ago — an increase of 1%. However, this performance […]
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) has reported a loss for its first fiscal quarter (ending March 31) of $-2.03 versus a loss $-2.33 for the same period a year ago. E.P.S. were $-8.03 for the […]
Extremely significant positive changes in Servotronics Inc. (NYSEAMERICAN: SVT) investment behavior have recently occurred: its longer term price trend turned up, the stock’s recent price rise disrupted its longer term downtrend, and positive upside/downside volume […]
For its first fiscal quarter (ending March 31), Exelon Corp (NASDAQ: EXC) has reported a -1% decline in E.P.S. from $0.67 a year ago to $0.66 in the current quarter. This performance was $-0.09 short […]
For its first fiscal quarter (ending March 31), Church & Dwight Co Inc (NYSE: CHD) has reported a 13% increase in E.P.S. from $0.83 a year ago to $0.94 in the current quarter. This performance […]
Agios Pharmaceuticals Inc (NASDAQ: AGIO) has reported a loss for its first fiscal quarter (ending March 31) of $-1.45 versus a loss $-1.47 for the same period a year ago. For the latest four quarters […]
On 5/2/24, Actinium Pharmaceuticals Inc (NYSEAMERICAN: ATNM) stock enjoyed a major increase of 12.5%, closing at $8.75. Moreover, unusually high trading volume at 158% of normal accompanied the advance. The stock has risen 23.9% during […]
Recent extremely meaningful negative changes in investment behavior have impacted The Clorox Co (NYSE: CLX): the stock’s recent price decline challenged its longer term uptrend, the stock fell on very heavy volume, and negative upside/downside […]
Repligen Corp (NASDAQ: RGEN) has reported E.P.S. of $0.04 for its first fiscal quarter (ending March 31) versus $0.52 for the same period a year ago — a decline of -92%. This result fell short […]
Stock Rating Downgrade The Value Trend Rating for NACCO Industries Inc. (NYSE: NC) weakened in recent days from C to D reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included […]
Privacy Statement Terms Of Use ©2024 PriceTarget Research